Corporate support helps the GI Cancer Institute unlock the answers to better treatments for the 28,600 Australians diagnosed with gastro-intestinal (GI) cancer each year.
With 39 Australians losing their battle to the disease every day, the stakes are high.
The GI Cancer Institute aims to raise money for GI cancer clinical trials research conducted by the Australasian Gastro-Intestinal Trials Group (AGITG). The AGITG is comprised of over 1,000 medical professionals who volunteer their time. AGITG research is conducted independently of the corporate supporters of the GI Cancer Institute.
We thank the following companies for their recent support.
Corporate Sponsors – Platinum
Servier possesses a unique cultural heritage as an international, independent, French research-based ethical pharmaceutical Company governed by a non-profit foundation. Servier produces innovative drugs for doctors and their patients around the world. At the same time, driven by the medical needs of humankind and advances in science and technology, Servier strives to meet the demands of the future.
Additional information can be found at www.servier.com.au.
Corporate Sponsors – Gold
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Additional information can be found at www.amgen.com.au
AstraZeneca is a global, science-led biopharmaceutical company that focuses
on the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas – Respiratory &
Autoimmunity, Cardiovascular & Metabolic Disease and Oncology.
The Company is also active in inflammation, infection and neuroscience through
numerous collaborations. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
Corporate Sponsors - Silver
Specialised Therapeutics is a bio-pharmaceutical company dedicated to working with leading international pharmaceutical and diagnostic companies to provide patient access to innovative healthcare solutions.
With the highest professional and ethical standards we commercialise therapies and technologies that uniquely fulfil the unmet medical needs of our community.
The Specialised Therapeutics portfolio and pipeline at present encompasses oncology, haematology, urology and ophthalmology.
In November 2014, ABRAXANE ® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine was listed on the Pharmaceutical Benefits Scheme for eligible patients with metastatic pancreatic cancer.
Additional information can be found at www.specialisedtherapeutics.com.au